Repetto L, Chiara S, Guido T, Bruzzone M, Oliva C, Ragni N, Conte P F, Rosso R
Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Anticancer Res. 1991 Jul-Aug;11(4):1641-3.
In ovarian cancer patients intraperitoneal chemotherapy confers pharmacokinetic advantages and appears an attractive way to improve the efficacy of certain antineoplastic agents. Intraperitoneal carboplatin and interferon alpha have been separately evaluated in ovarian cancer "with promising results". We report a phase I-II pilot trial of intraperitoneal carboplatin 400 mg/sqm plus interferon alpha 25 x 10(6) U q 28 d in 16 patients (pts) previously treated with intravenous cisplatin based chemotherapy. All the patients had relapsed (11 pts) or refractory (5 pts) disease; residual tumors were less than 2 cm in 10 pts and greater than 2 cm in 6 pts. Local and general toxicities were moderate, with neither WHO grade 4, nor neurotoxicity and ototoxicity. Myelotoxicity was the most frequent side effect. Among 14 evaluable pts, objective responses were observed in 6 pts (42.8%) including 3 pts with pathologically confirmed complete response (21.4%); six more pts presented prolonged disease-free survival. Response occurred in both categories of pts with greater than or less than 2 cm residual disease, also in pts refractory to prior intravenous cisplatin. The proper role of intraperitoneal treatment cannot be exactly defined without large randomized trials designed to compare intraperitoneal to intravenous drug administrations.
在卵巢癌患者中，腹腔内化疗具有药代动力学优势，似乎是提高某些抗肿瘤药物疗效的一种有吸引力的方法。腹腔内注射卡铂和α干扰素已分别在卵巢癌中进行评估，“结果令人鼓舞”。我们报告了一项I-II期试点试验，对16例先前接受过基于静脉顺铂化疗的患者给予腹腔内注射卡铂400mg/m²加α干扰素25×10⁶U，每28天一次。所有患者均为复发（11例）或难治性（5例）疾病；10例患者残留肿瘤小于2cm，6例患者残留肿瘤大于2cm。局部和全身毒性为中度，无WHO 4级毒性，也无神经毒性和耳毒性。骨髓毒性是最常见的副作用。在14例可评估的患者中，6例（42.8%）观察到客观缓解，其中3例经病理证实为完全缓解（21.4%）；另外6例患者无病生存期延长。残留疾病大于或小于2cm的两类患者均出现缓解，先前接受静脉顺铂治疗难治的患者也出现缓解。如果没有旨在比较腹腔内给药与静脉内给药的大型随机试验，就无法准确界定腹腔内治疗的恰当作用。
